Profile data is unavailable for this security.
About the company
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
- Revenue in USD (TTM)0.00
- Net income in USD-121.83m
- Incorporated2016
- Employees128.00
- LocationPrelude Therapeutics Inc175 Innovation BoulevardWILMINGTON 19805United StatesUSA
- Phone+1 (302) 467-1280
- Fax+1 (302) 658-3989
- Websitehttps://preludetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acumen Pharmaceuticals Inc | 0.00 | -52.37m | 195.26m | 51.00 | -- | 0.705 | -- | -- | -1.08 | -1.08 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -20.67 | -- | -21.56 | -- | -- | -- | -- | -- | -- | -- | 0.103 | -- | -- | -- | -22.20 | -- | -- | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 196.72m | 459.00 | -- | -- | -- | 1.90 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| Omeros Corp | 0.00 | -174.92m | 197.01m | 198.00 | -- | -- | -- | -- | -2.79 | -1.88 | 0.00 | -0.4087 | 0.00 | -- | -- | 0.00 | -36.09 | -55.51 | -44.88 | -70.10 | -- | -- | -- | -- | -- | -5.33 | 1.08 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Trevi Therapeutics Inc | 0.00 | -29.07m | 197.23m | 25.00 | -- | 2.37 | -- | -- | -0.2934 | -0.2934 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -27.37 | -47.39 | -30.09 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| CervoMed Inc | 7.14m | -2.17m | 199.49m | 8.00 | -- | 18.59 | -- | 27.92 | -0.6282 | -0.6282 | 2.07 | 1.30 | 0.4382 | -- | -- | 893,108.80 | -13.32 | -53.67 | -15.74 | -58.89 | -- | -- | -30.40 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Zevra Therapeutics Inc | 27.46m | -46.05m | 199.76m | 65.00 | -- | 3.09 | -- | 7.27 | -1.29 | -1.29 | 0.7746 | 1.49 | 0.1909 | -- | 2.14 | 422,476.90 | -32.02 | -32.11 | -45.61 | -39.89 | 45.22 | -- | -167.69 | -128.42 | -- | -- | 0.4058 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -13.07m | 202.09m | 1.00 | -- | 56.79 | -- | -- | -0.48 | -0.48 | 0.00 | 0.1202 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.40 | 0.0285 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Adverum Biotechnologies Inc | 3.60m | -117.17m | 203.19m | 121.00 | -- | 1.19 | -- | 56.44 | -11.62 | -11.62 | 0.3571 | 8.23 | 0.015 | -- | -- | 29,752.07 | -48.68 | -36.39 | -55.24 | -39.04 | -- | -- | -3,254.58 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Design Therapeutics Inc | 0.00 | -66.86m | 204.51m | 58.00 | -- | 0.7362 | -- | -- | -1.19 | -1.19 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -21.20 | -- | -21.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Prelude Therapeutics Inc | 0.00 | -121.83m | 204.85m | 128.00 | -- | 0.8639 | -- | -- | -2.05 | -2.05 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -48.91 | -47.21 | -53.60 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 208.20m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Renovaro Inc | 0.00 | -41.23m | 211.19m | 12.00 | -- | 2.29 | -- | -- | -0.685 | -0.685 | 0.00 | 0.6431 | 0.00 | -- | -- | 0.00 | -59.63 | -27.81 | -72.82 | -28.44 | -- | -- | -- | -- | -- | -22.12 | 0.1299 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Eliem Therapeutics Inc | 0.00 | -35.12m | 212.29m | 9.00 | -- | 1.95 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Lineage Cell Therapeutics Inc | 8.95m | -21.49m | 213.04m | 75.00 | -- | 3.12 | -- | 23.82 | -0.1243 | -0.1243 | 0.0518 | 0.3624 | 0.0796 | -- | 17.17 | 119,266.70 | -19.12 | -19.53 | -22.55 | -22.59 | 92.50 | 89.13 | -240.12 | -370.88 | -- | -- | 0.0023 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| G1 Therapeutics Inc | 82.51m | -47.97m | 215.58m | 100.00 | -- | 6.06 | -- | 2.61 | -0.953 | -0.953 | 1.53 | 0.6815 | 0.5332 | 0.5028 | 6.94 | 825,110.00 | -31.00 | -47.06 | -39.28 | -52.64 | 91.28 | -- | -58.13 | -268.59 | 3.45 | -5.22 | 0.593 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -42.49m | 216.02m | 32.00 | -- | 1.35 | -- | -- | -0.3343 | -0.3343 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -23.84 | -41.75 | -25.56 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
Data as of May 02 2024. Currency figures normalised to Prelude Therapeutics Inc's reporting currency: US Dollar USD
27.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2023 | 10.12m | 18.43% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 1.03m | 1.87% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 995.70k | 1.81% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 920.21k | 1.68% |
| Massachusetts Financial Services Co.as of 31 Dec 2023 | 510.75k | 0.93% |
| Geode Capital Management LLCas of 31 Dec 2023 | 349.37k | 0.64% |
| Sio Capital Management LLCas of 31 Dec 2023 | 320.39k | 0.58% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 264.58k | 0.48% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 241.18k | 0.44% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 216.40k | 0.39% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
